Lightbridge Q2 2026 earnings: R&D spending widens the net loss

Lightbridge (Nasdaq: LTBR) reported no revenue in fiscal Q2 2026, unchanged from Q2 2025, while basic and diluted loss per share was $0.18 versus $0.16 a year earlier. Net loss widened to $5.8 million as research and development and administrative spending increased, although higher interest income provided a partial offset. Cash reached $237.5 million at June 30, supported by first-half equity financing rather than operating cash generation.

Key quarterly results

For the quarter ended June 30, total operating expenses increased to $7.6 million from $4.1 million. R&D accounted for most of the increase, reflecting higher compensation and stock-based compensation, additional project development work, and increased Idaho National Laboratory labor costs.

G&A expense also rose as Lightbridge added employees, increased bonuses and issued new stock-based awards. Interest income increased to $1.9 million because the company held higher average cash balances, reducing the gap between its $7.6 million operating loss and $5.8 million net loss.

The reported expense figures include a $0.7 million reversal of previously recognized stock-based compensation after a performance condition was judged no longer probable of being achieved. Even with that reversal, combined stock-based compensation included in quarterly G&A and R&D expenses was approximately $1.4 million, compared with $0.7 million a year earlier.

Fuel development and commercialization progress

Lightbridge remains a pre-revenue fuel technology developer, making technical milestones more relevant than commercial sales at this stage. In May, the first batch of fuel material samples was removed from Idaho National Laboratory’s Advanced Test Reactor. The samples are cooling before post-irradiation examination, which management expects to begin later in 2026, while irradiation of the remaining samples continues.

The examination is intended to provide the company’s first material-property data under high burn-up conditions. Lightbridge also received notices of allowance covering its multi-lobed fuel assembly in the United States and its multi-zone fuel element and additive manufacturing method across 39 European Patent Office contracting states.

During the quarter, Lightbridge partnered with Studsvik Scandpower to develop an extension of the CMS5 Core Management Suite that can model the Lightbridge Fuel design. After quarter-end, the company signed a memorandum of understanding with Quadrant Nuclear Industries to establish a framework for potential long-term HALEU supply from Quadrant’s planned Vanguard facility at Idaho National Laboratory.

Equity financing lifted liquidity while the share count rose

For the first six months of 2026, operating activities used $8.3 million of cash, up from $5.6 million in the prior-year period. The increase reflected higher R&D and G&A cash expenditures, partially offset by increased interest income. First-half net loss was $12.1 million, while $3.9 million of stock-based compensation helped explain why operating cash use was lower than the accounting loss.

Financing activities generated $43.9 million during the first half, compared with $63.5 million a year earlier. Lightbridge sold 3.8 million shares through its ATM equity program, down from 6.2 million shares in the comparable period. These financing proceeds more than offset operating cash use, raising cash and cash equivalents by $35.6 million from year-end to $237.5 million. Working capital increased to $236.4 million from $201.7 million at December 31, 2025.

The added liquidity came with a larger equity base. Common shares outstanding increased to 37.4 million at June 30 from 33.4 million at year-end, while the quarterly weighted-average share count rose to 31.9 million from 22.3 million a year earlier. That higher denominator limited the increase in per-share loss even though the absolute net loss expanded more substantially.

Risks investors should monitor

• No current revenue: Lightbridge remains dependent on successful testing, qualification and eventual adoption of its nuclear fuel technology before it can establish commercial revenue.
• Rising development costs: The sharp increase in R&D and G&A expenses widened both quarterly and first-half losses. Continued technical work and hiring could keep operating cash use elevated.
• Reliance on equity financing: The cash balance increased because of share issuance rather than operating inflows. Further ATM activity could continue increasing the share count.
• Testing and supply dependencies: Development progress depends on access to Idaho National Laboratory resources, completion of irradiation examinations and future manufacturing and HALEU availability. Delays or higher project costs could extend the commercialization timeline.

Summary

Lightbridge’s fiscal Q2 2026 results reflect a development-stage company increasing spending on fuel testing, technical personnel and related projects while remaining pre-revenue. Higher interest income softened the effect of rising operating expenses, and ATM financing left the company with substantial liquidity, but also increased its share count. The main items to monitor are post-irradiation examination progress, the pace of operating cash use and how the company balances future development funding with additional equity issuance.